Experimental drug combo targets Tough-to-Treat bile duct cancer
NCT ID NCT07151872
Summary
This study is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps control advanced bile duct cancer that has a specific marker called CLDN18.2. Researchers will enroll 120 patients who haven't received prior treatment for their advanced cancer to see if the combination shrinks tumors and is safe. The goal is to find better treatment options for this difficult cancer type.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLDN18.2-POSITIVE ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.